Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease-Reference-Cited by-同舟云学术

Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease

Published:2015-08 Issue:8 Volume:90 Page:1030-1037
ISSN:0025-6196
Container-title:Mayo Clinic Proceedings
language:en
Short-container-title:Mayo Clinic Proceedings

Author:

Hogan Marie C.,Masyuk Tetyana,Bergstralh Eric,Li Bill,Kremers Walter K.,Vaughan Lisa E.,Ihrke Angela,Severson Amanda L.,Irazabal Maria V.,Glockner James,LaRusso Nicholas F.,Torres Vicente E.

Publisher

Elsevier BV

Subject

General Medicine

Reference21 articles.

1. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort;Bae;Clin J Am Soc Nephrol,2006

2. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease;Ruggenenti;Kidney Int,2005

3. Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide;Caroli;Clin J Am Soc Nephrol,2010

4. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial;van Keimpema;Gastroenterology,2009

5. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease;Hogan;J Am Soc Nephrol,2010

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights;Expert Opinion on Investigational Drugs;2024-04-21

2. ACG Clinical Guideline: Focal Liver Lesions;American Journal of Gastroenterology;2024-01-26

3. Extrarenal Manifestations: Polycystic Liver Disease and Its Complications;Advances in Kidney Disease and Health;2023-09

4. Development and Validation of a Nomogram for Renal Survival Prediction in Patients with Autosomal Dominant Polycystic Kidney Disease;Kidney Diseases;2023-06-06

5. Concurrent Targeting of Vasopressin Receptor 2 and Somatostatin Receptors in Autosomal Dominant Polycystic Kidney Disease: A Promising Approach for Autosomal Dominant Polycystic Kidney Disease Treatment?;Clinical Journal of the American Society of Nephrology;2023-01-16